297 research outputs found
Strategies for cellular decision-making
Get PDFStochasticity pervades life at the cellular level. Cells receive stochastic signals, perform detection and transduction with stochastic biochemistry, and grow and die in stochastic environments. Here we review progress in going from the molecular details to the information-processing strategies cells use in their decision-making. Such strategies are fundamentally influenced by stochasticity. We argue that the cellular decision-making can only be probabilistic and occurs at three levels. First, cells must infer from noisy signals the probable current and anticipated future state of their environment. Second, they must weigh the costs and benefits of each potential response, given that future. Third, cells must decide in the presence of other, potentially competitive, decision-makers. In this context, we discuss cooperative responses where some individuals can appear to sacrifice for the common good. We believe that decision-making strategies will be conserved, with comparatively few strategies being implemented by different biochemical mechanisms in many organisms. Determining the strategy of a decision-making network provides a potentially powerful coarse-graining that links systems and evolutionary biology to understand biological design
Chemotaxis When Bacteria Remember: Drift versus Diffusion
Get PDF{\sl Escherichia coli} ({\sl E. coli}) bacteria govern their trajectories by
switching between running and tumbling modes as a function of the nutrient
concentration they experienced in the past. At short time one observes a drift
of the bacterial population, while at long time one observes accumulation in
high-nutrient regions. Recent work has viewed chemotaxis as a compromise
between drift toward favorable regions and accumulation in favorable regions. A
number of earlier studies assume that a bacterium resets its memory at tumbles
-- a fact not borne out by experiment -- and make use of approximate
coarse-grained descriptions. Here, we revisit the problem of chemotaxis without
resorting to any memory resets. We find that when bacteria respond to the
environment in a non-adaptive manner, chemotaxis is generally dominated by
diffusion, whereas when bacteria respond in an adaptive manner, chemotaxis is
dominated by a bias in the motion. In the adaptive case, favorable drift occurs
together with favorable accumulation. We derive our results from detailed
simulations and a variety of analytical arguments. In particular, we introduce
a new coarse-grained description of chemotaxis as biased diffusion, and we
discuss the way it departs from older coarse-grained descriptions.Comment: Revised version, journal reference adde
Woody lianas increase in dominance and maintain compositional integrity across an Amazonian dam-induced fragmented landscape
Get PDFTropical forest fragmentation creates insular biological communities that undergo species loss and changes in community composition over time, due to area- and edge-effects. Woody lianas thrive in degraded and secondary forests, due to their competitive advantage over trees in these habitats. Lianas compete both directly and indirectly with trees, increasing tree mortality and turnover. Despite our growing understanding of liana-tree dynamics, we lack detailed knowledge of the assemblage-level responses of lianas themselves to fragmentation, particularly in evergreen tropical forests. We examine the responses of both sapling and mature liana communities to landscape-scale forest insularization induced by a mega hydroelectric dam in the Brazilian Amazon. Detailed field inventories were conducted on islands created during reservoir filling, and in nearby mainland continuous forest. We assess the relative importance of variables associated with habitat fragmentation such as area, isolation, surrounding forest cover, fire and wind disturbance, on liana community attributes including abundance, basal area, diversity, and composition. We also explore patterns of liana dominance relative to tree saplings and adults ≥10 cm diameter at breast height. We find that 1) liana community composition remains remarkably similar across mainland continuous forest and islands, regardless of extreme area- and edge- effects and the loss of vertebrate dispersers in the latter; and 2) lianas are increasing in dominance relative to trees in the sapling layer in the most degraded islands, with both the amount of forest cover surrounding islands and fire disturbance history predicting liana dominance. Our data suggest that liana communities persist intact in isolated forests, regardless of extreme area- and edge-effects; while in contrast, tree communities simultaneously show evidence of increased turnover and supressed recruitment. These processes may lead to lianas becoming a dominant component of this dam-induced fragmented landscape in the future, due to their competitive advantage over trees in degraded forest habitats. Additional loss of tree biomass and diversity brought about through competition with lianas, and the concurrent loss of carbon storage, should be accounted for in impact assessments of future dam development
Weak pairwise correlations imply strongly correlated network states in a neural population
Get PDFBiological networks have so many possible states that exhaustive sampling is
impossible. Successful analysis thus depends on simplifying hypotheses, but
experiments on many systems hint that complicated, higher order interactions
among large groups of elements play an important role. In the vertebrate
retina, we show that weak correlations between pairs of neurons coexist with
strongly collective behavior in the responses of ten or more neurons.
Surprisingly, we find that this collective behavior is described quantitatively
by models that capture the observed pairwise correlations but assume no higher
order interactions. These maximum entropy models are equivalent to Ising
models, and predict that larger networks are completely dominated by
correlation effects. This suggests that the neural code has associative or
error-correcting properties, and we provide preliminary evidence for such
behavior. As a first test for the generality of these ideas, we show that
similar results are obtained from networks of cultured cortical neurons.Comment: Full account of work presented at the conference on Computational and
Systems Neuroscience (COSYNE), 17-20 March 2005, in Salt Lake City, Utah
(http://cosyne.org
Stimulus-dependent maximum entropy models of neural population codes
Get PDFNeural populations encode information about their stimulus in a collective
fashion, by joint activity patterns of spiking and silence. A full account of
this mapping from stimulus to neural activity is given by the conditional
probability distribution over neural codewords given the sensory input. To be
able to infer a model for this distribution from large-scale neural recordings,
we introduce a stimulus-dependent maximum entropy (SDME) model---a minimal
extension of the canonical linear-nonlinear model of a single neuron, to a
pairwise-coupled neural population. The model is able to capture the
single-cell response properties as well as the correlations in neural spiking
due to shared stimulus and due to effective neuron-to-neuron connections. Here
we show that in a population of 100 retinal ganglion cells in the salamander
retina responding to temporal white-noise stimuli, dependencies between cells
play an important encoding role. As a result, the SDME model gives a more
accurate account of single cell responses and in particular outperforms
uncoupled models in reproducing the distributions of codewords emitted in
response to a stimulus. We show how the SDME model, in conjunction with static
maximum entropy models of population vocabulary, can be used to estimate
information-theoretic quantities like surprise and information transmission in
a neural population.Comment: 11 pages, 7 figure
Phenomenological analysis of ATP dependence of motor protein
Get PDFIn this study, through phenomenological comparison of the velocity-force data
of processive motor proteins, including conventional kinesin, cytoplasmic
dynein and myosin V, we found that, the ratio between motor velocities of two
different ATP concentrations is almost invariant for any substall, superstall
or negative external loads. Therefore, the velocity of motor can be well
approximated by a Michaelis-Menten like formula V=\atp k(F)L/(\atp +K_M),
with the step size, and the external load dependent rate of one
mechanochemical cycle of motor motion in saturated ATP solution. The difference
of Michaelis-Menten constant for substall, superstall and negative
external load indicates, the ATP molecule affinity of motor head for these
three cases are different, though the expression of as a function of
might be unchanged for any external load . Verifications of this
Michaelis-Menten like formula has also been done by fitting to the recent
experimental data
A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients
Get PDF<p>Abstract</p> <p>Background</p> <p>Lumiracoxib is a selective cyclooxygenase-2 inhibitor effective in the treatment of osteoarthritis (OA) with a superior gastrointestinal (GI) safety profile as compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs, ibuprofen and naproxen). This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA. Rofecoxib was withdrawn worldwide due to an associated increased risk of CV events and lumiracoxib has been withdrawn from Australia, Canada, Europe and a few other countries following reports of suspected adverse liver reactions.</p> <p>Methods</p> <p>This randomised, double-blind study enrolled 309 patients (aged greater than or equal to 50 years) with primary OA across 51 centres in Europe. Patients were randomly allocated to receive either lumiracoxib 400 mg od (four times the recommended dose in OA) (<it>n </it>= 154) or rofecoxib 25 mg od (<it>n </it>= 155). The study was conducted for 6 weeks and assessments were performed at Weeks 3 and 6. The primary safety measures were the incidence of predefined GI adverse events (AEs) and peripheral oedema. The secondary safety measures included effect of treatment on the mean sitting systolic and diastolic blood pressure (msSBP and msDBP). Tolerability of lumiracoxib 400 mg was assessed by the incidence of AEs.</p> <p>Results</p> <p>Lumiracoxib and rofecoxib displayed similar GI safety profiles with no statistically significant difference in predefined GI AEs between the two groups (43.5% <it>vs</it>. 37.4%, respectively). The incidence and severity of individual predefined GI AEs was comparable between the two groups. The incidence of peripheral oedema was low and identical in both the groups (<it>n </it>= 9, 5.8%). Only one patient in the lumiracoxib group and three patients in the rofecoxib group had a moderate or severe event. At Week 6 there was a significantly lower msSBP and msDBP in the lumiracoxib group compared to the rofecoxib group (<it>p </it>< 0.05). A similar percentage of patients in both groups showed an improvement in target joint pain and disease activity. The tolerability profile was similar in both the treatment groups.</p> <p>Conclusion</p> <p>Lumiracoxib 400 mg od (four times the recommended dose in OA) provided a comparable GI safety profile to rofecoxib 25 mg od (therapeutic dose). However, lumiracoxib was associated with a significantly better BP profile as compared to rofecoxib.</p> <p>Trial registration number -</p> <p>NCT00637949</p
Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice
Get PDFBACKGROUND: Gastrointestinal harm, known to occur with NSAIDs, is thought to be lower with NSAID and gastroprotective agent, and with inhibitors selective to cyclooxygenase-2 (coxibs) at usual plasma concentrations. We examine competing strategies for available evidence of reduced gastrointestinal bleeding in clinical trials and combine this evidence with evidence from clinical practice on whether the strategies work in the real world, whether guidance on appropriate prescribing is followed, and whether patients adhere to the strategies. METHODS: We used a series of systematic literature searches to find full publications of relevant studies for evidence about the efficacy of these different gastroprotection strategies in clinical trials, and for evidence that they worked and were adhered to in clinical practice – whether they were effective. We chose to use good quality systematic reviews and meta-analyses when they were available. RESULTS: Evidence of efficacy of coxibs compared to NSAIDs for upper gastrointestinal bleeding was strong, with consistent reductions in events of about 50% in large randomised trials (34,460 patients), meta-analyses of randomised trials (52,474 patients), and large observational studies in clinical practice (3,093 bleeding events). Evidence on the efficacy of NSAID plus gastroprotection with acid suppressants (proton pump inhibitors, PPIs, and histamine antagonists, H2As) was based mainly on the surrogate measure of endoscopic ulcers. The limited information on damage to the bowel suggested that NSAID plus PPI was more damaging than coxibs. Eleven observational studies studied 1.6 million patients, of whom 911,000 were NSAID users, and showed that 76% (range 65% to 90%) of patients with at least one gastrointestinal risk factor received no prescription for gastroprotective agent with an NSAID. The exception was a cohort of US veterans with previous gastrointestinal bleeding, where 75% had gastroprotection with an NSAID. When gastroprotection was prescribed, it was often described as inadequate. A single study suggested that patient adherence to prescribed gastroprotection was low. CONCLUSION: Evidence for efficacy of gastroprotection strategies with NSAIDs is limited. In clinical practice few patients who need gastroprotection get it, and those who get it may not take it. For coxibs, gastroprotection is inherent, although probably not complete
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]
Get PDFBACKGROUND: Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA). METHODS: Double-blind, randomized, placebo and active comparator-controlled, 12-week study conducted at 67 sites in 28 countries. Eligible patients were chronic NSAID users who demonstrated a clinical worsening of arthritis upon withdrawal of prestudy NSAIDs. Patients received either placebo, etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1 allocation ratio). Primary efficacy measures included direct assessment of arthritis by counts of tender and swollen joints, and patient and investigator global assessments of disease activity. Key secondary measures included the Stanford Health Assessment Questionnaire, patient global assessment of pain, and the percentage of patients who achieved ACR20 responder criteria response (a composite of pain, inflammation, function, and global assessments). Tolerability was assessed by adverse events and routine laboratory evaluations. RESULTS: 1171 patients were screened, 891 patients were randomized (N = 357 for placebo, N = 353 for etoricoxib, and N = 181 for naproxen), and 687 completed 12 weeks of treatment (N = 242 for placebo, N = 294 for etoricoxib, and N = 151 for naproxen). Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p<0.05). Treatment responses were similar between the etoricoxib and naproxen groups for all endpoints. The percentage of patients who achieved ACR20 responder criteria response was 41% in the placebo group, 59% in the etoricoxib group, and 58% in the naproxen group. Etoricoxib and naproxen were both generally well tolerated. CONCLUSIONS: In this study, etoricoxib 90 mg once daily was more effective than placebo and similar in efficacy to naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg was generally well tolerated in RA patients
Pressure is not a state function for generic active fluids
Get PDFPressure is the mechanical force per unit area that a confined system exerts
on its container. In thermal equilibrium, it depends only on bulk properties
(density, temperature, etc.) through an equation of state. Here we show that in
a wide class of active systems the pressure depends on the precise interactions
between the active particles and the confining walls. In general, therefore,
active fluids have no equation of state, their mechanical pressures exhibit
anomalous properties that defy the familiar thermodynamic reasoning that holds
in equilibrium. The pressure remains a function of state, however, in some
specific and well-studied active models that tacitly restrict the character of
the particle-wall and/or particle-particle interactions.Comment: 8 pages + 9 SI pages, Nature Physics (2015
- …
